ALS and MS are chronic neurological disorders that involve progressive or intermittent deterioration of various neurological functions, including motor skills, sensory perception, vision, and cognition.

Our team of dedicated healthcare professionals are committed to improving the quality of life for people living with these neurological conditions using a patient-centred approach.

With BRAINTEASER we stay up to date with the latest research and treatment options to deliver the most effective therapies available while continuing to use a broad range of services to address all aspects of patient care:

  • Personalized rehabilitation programs that focus on maximizing mobility, strength and independence to improve their daily activities
  • Speech language techniques and exercises to improve communication skills and ensure safe and efficient swallowing
  • Psychological and emotional aid throughout the trip. We offer counseling services and support groups to help patients and their loved ones overcome the emotive impact of these conditions and build resilience
  • Staying at the forefront of scientific advances, we aim to provide our patients with access to innovative treatments and potential breakthroughs in the field of neurology.

BRAINTEASER uses a mobile app and low-cost sensors to record environmental data such as pollution, temperature and clinical data of different nature such as oximetry and heartbeats, to build mathematical models that will merge those data to better understand the epidemiology of ALS and MS.

Our goal is to gain a deeper understanding of the onset and varying progression of ALS and MS among patients, enabling us to explore novel treatment approaches.


The Lisbon Academic Medical Center (Centro Académico de Medicina de Lisboa-CAML) is an innovative academic centre and a consortium of three institutions: one of the main portuguese hospitals – North Lisbon University Hospital Center (Centro Hospitalar Universitário Lisboa Norte-CHULN), a Medical School – Lisbon School of Medicine (Faculdade de Medicina da Universidade de Lisboa-FMUL) – and a biomedical research institute of excellence – Instituto de Medicina Molecular João Lobo Antunes (IMM).

IRCCS Mondino MS Centre

The Multiple Sclerosis Centre of Pavia is part of the IRCCS National Neurological Institute Mondino, a scientific Institute for research, hospitalization and healthcare, entirely dedicated to neurological diseases affecting all ages (from childhood to elderly). 

The MS Center is regularly following about 1500 patients, with 7 outpatients/week and 2 inpatient beds.

CRESLA Torino and Turin MS Centre

The Turin ALS Centre (CRESLA Torino) is part of the “Rita Levi Montalcini” Department of Neuroscience of the University of Turin (UNITO). UNITO is one of the largest Italian universities, with about 80.000 students, 3.900 employees, 1.800 post-graduate and post-doctoral research fellows.

Hospital Universitario Gregorio Marañón/SERMAS-Madrid

Gregorio Marañón University Hospital (Hospital Universitario Gregorio Marañón) belongs to Servicio Madrileño de Salud: SERMAS (Madrid Health Service), and stands out for the high training and qualification of its professionals, for its teaching and research capacity and for its technological endowment, being a national and international reference in various specialties.

By embracing precision medicine, BRAINTEASER will allow doctors to have the necessary
data -all at a single glance- to support informed decisions that consider the panoramic
context of patient progress, including general health and socio-economic situations.

As a consequence of proposing stratification and prediction models for clinical practice use,
BRAINTEASER will provide tools that can be employed as in silico simulators and help design
clinical trials and develop drugs, as well as supportive clinical decision-making software in
compliance with ongoing regulation recommendations.

Skip to content